Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450399 | 0.82 | LMNA (0.58) | POLBATMGAASMN1; SMN2CYP1A2 | |
| SCHEMBL9311982 | 0.82 | ALDH1A1 (0.44) | POLBATMGAASMN1; SMN2CYP1A2 | |
| SCHEMBL9311503 | 0.80 | EPHX1 (0.62) | GAASMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18509790 | 0.77 | ESR2 (0.42) | POLBSMN1; SMN2CYP1A2CYP2C19LMNA | |
| SCHEMBL9311637 | 0.76 | SMN1; SMN2 (0.68) | GAASMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11542705 | 0.75 | GAA (0.73) | POLBATMGAASMN1; SMN2MAPT | |
| SCHEMBL16351359 | 0.73 | ALDH1A1 (0.47) | SMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL9059999 | 0.73 | SMN1; SMN2 (0.39) | POLBGAASMN1; SMN2MAPTLMNA | |
| SCHEMBL15484311 | 0.72 | LMNA (0.69) | POLBATMGAASMN1; SMN2CYP1A2 | |
| SCHEMBL11542857 | 0.72 | ALDH1A1 (0.65) | POLBGAASMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996017612-A1 | USE OF SUBSTITUTED PHENYLAMIDINE AND PHENYLGUANIDINE COMPOUNDS FOR THE TREATMENT OF CEREBRAL AND CARDIAC ISCHAEMIA, CONVULSION AND SICKLE CELL ANAEMIA | KNOLL AKTIENGESELLSCHAFT (DE) | 1996-06-13 | — | — | WO | disclosed |